Study of the Safety and Pharmacokinetics of Olaratumab (IMC-3G3) in Japanese Participants With Solid Tumors

NCT01199822 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignancy
Metastasis

Interventions

BIOLOGICAL: Olaratumab

Sponsor

Eli Lilly and Company